NOTICE: Thank you for visiting our site. Your experience is important to us. We're upgrading our system to better serve you. During this time, purchases and member logins will be unavailable. Full functionality will be restored by Monday, 29 July.
NOTICE: Thank you for visiting our site. Your experience is important to us. We're upgrading our system to better serve you. During this time, purchases and member logins will be unavailable. Full functionality will be restored by Monday, 29 July.
The global pandemic is impacting supply chains worldwide, but pharmaceutical supply chains are especially vulnerable. Manufacturers are under pressure to help maintain the supply of critical medicines during COVID-19 as well as contribute to the on-going efforts to support the ever-changing supply chain.
As pharmaceutical manufacturers reprioritize production due to changing and increased product demand, many don’t have alternate suppliers for critical components. This has been a game-changer as they not only have to identify new suppliers, but they must also qualify these components to ensure they understand impact on process, and that quality meets the required standards.
Manufacturing partners across geographic regions are navigating this “new normal” under stressful conditions exacerbated by increased demand for APIs, new supply chain challenges, and an ever-increasing global focus on maintaining quality. To truly succeed as an industry, we must knowledge share and problem-solve together to advance and proactively prepare for the continued success of our mission as an industry.
As Co-Chairs of the 2020 ISPE Asia Pacific Pharma Manufacturing Virtual Conference & Executive Forum, we invite you to join us for this collaborative forum where you can learn and ask questions on key trends, best practices, and regulatory perspectives for maintaining pharma supply chain reliance, overall quality, and compliance sustainability.
Nowhere else can you participate in actionable, interactive discussions featuring case studies and dedicated Q&A time with experts representing FDA, MHRA, local health authorities, Pfizer, Biocon, and more as they answer questions like:
You can submit your questions on the event homepage prior to the conference or ask your questions in real-time. Stay knowledgeable throughout the year with on demand access to all session recordings and presentations for one year.
Collaboration is a crucial element in mitigating the impact of COVID-19 on the pharmaceutical supply chain. We encourage you to register today to ensure you have the strategies to make your operations more agile, compliant, and resilient to disruption.
The pharmaceutical industry stands at the cusp of a transformative era, where the integration of sustainability within the supply chain is not just a trend, but a necessity. The 2024 ISPE Annual Meeting &...
Although parenteral products make up only 1% of global pharmaceutical prescriptions by volume, at list price they now make up nearly half of global sales value, a percentage that has been increasing. Many of these are complex products produced in smaller batches for immunology or oncology, and a large majority are biologic therapies, which are generally poorly suited to oral formulations.
In 2020, CSL initiated a benchmarking activity with a small group of peer companies identified through ISPE to explore creation and maturation of asset management programs at each company. The initial sessions were a success, covering topics such as asset condition evaluations and asset management governance. CSL was keen to continue the conversations and gather more insights on certain...